Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Sat Mar 7, 5:10AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Omada Health, Inc. (OMDAResearch Report) and Owlet (OWLTResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Omada Health, Inc. (OMDA)

Needham analyst Ryan MacDonald reiterated a Buy rating on Omada Health, Inc. today and set a price target of $28.00. The company’s shares closed last Thursday at $13.60.

According to TipRanks.com, MacDonald is ranked 0 out of 5 stars with an average return of -10.4% and a 36.1% success rate. MacDonald covers the Technology sector, focusing on stocks such as ODDITY Tech Ltd. Class A, Waystar Holding Corp., and Duolingo. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omada Health, Inc. with a $24.71 average price target, representing an 83.0% upside. In a report issued on February 23, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Owlet (OWLT)

William Blair analyst Andrew Brackmann reiterated a Buy rating on Owlet today. The company’s shares closed last Thursday at $11.75.

According to TipRanks.com, Brackmann is a 4-star analyst with an average return of 14.8% and a 52.5% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Owlet has an analyst consensus of Strong Buy, with a price target consensus of $19.50.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.